Latest investments in "disease diagnostics

Integral service around a transaction
BY : Diego GutiérrezDecember Tue, 2013

venture capital isBiotech companies are developing new test systems to detect diseases as early as possible. The venture capital is is no stranger to this trend and in the month of December alone, more than 15 operations of fundingin a field dominated by the venture capital is pharmaceutical companies.

"The disease diagnosis activity has been in full swing throughout the year, with more than 100 operations of funding throughout the year. The most successful ones have been around for quite a few years because it is a sector that requires patience from investors, but these companies have demonstrated with facts their capacity to bring a product to the market", analyses Diego Gutierrez from Abra Invest.

The companies that stand out for having attracted the largest amount of investment were:

Vermillion $74M for diagnosis of women's diseases

Vermillion, located in Austin USA and founded in 1993, has been awarded a financing round of 1TP2Q17.3M in December 2013 led by the fund Oracle Investment Management, a specialist in the health sector. The company is dedicated to the development and commercialisation of high-value markers and diagnostic tests that address unmet needs in oncology, gynaecology and women's health.

Biodesix $67.6M for lung cancer screening

Biodesix offers VeriStrat, a serum protein test that helps physicians choose therapy for patients with advanced non-small cell lung cancer (NSCLC). The test is now commercially available and provides oncologists with the information needed to select between erlotinib and single-agent chemotherapy for patients with advanced lung cancer. The tests are processed in the CLIA-certified laboratory. Biodesix 'and the results are presented in less than 72 hours. In December 2013 it closed one round $8.3M of which $4.3M are new funds and another $4M from the conversion of convertible bonds.

Rheonix $42.1M for Biomedical Devices

Rheonix, Inc.. operates as a biomedical device company. Its products include CARD (Chemistry and Reagent Device) to miniaturise and automate new and existing assays in various fields. Its products and technologies are used in human/veterinary, in vitro diagnostics, food/water analysis, SNP analysis for customised medicine applications, homeland security/defence applications, process control and final product quality control and tissue culture analysis in a research or production context. It has closed in December 2013 a round of $12M provided by Rand Capital and Cayuga Venture Fund, which already contributed another $6M in a series A round in 2010.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?